Search tips
Search criteria 


Logo of jscJournal's HomeManuscript SubmissionAims and ScopeAuthor GuidelinesEditorial BoardHome
J Skin Cancer. 2011; 2011: 541405.
Published online 2010 December 27. doi:  10.1155/2011/541405
PMCID: PMC3017908

Deciphering Squamous Cell Carcinoma Using Multidimensional Genomic Approaches


Squamous cell carcinomas (SqCCs) arise in a wide range of tissues including skin, lung, and oral mucosa. Although all SqCCs are epithelial in origin and share common nomenclature, these cancers differ greatly with respect to incidence, prognosis, and treatment. Current knowledge of genetic similarities and differences between SqCCs is insufficient to describe the biology of these cancers, which arise from diverse tissue origins. In this paper we provide a general overview of whole genome approaches for gene and pathway discovery and highlight the advancement of integrative genomics as a state-of-the-art technology in the study of SqCC genetics.

1. Introduction

Squamous cell carcinoma (SqCC) initiation and development is characterized by the accumulation of genetic alterations. Over the past two decades, technological advances used to identify these alterations have expanded from single-gene queries to genome-wide methods of analysis in a multitude of dimensions, including genomics, epigenomics, and transcriptomics. Mutations and copy number alterations at the DNA level represent genomic alterations, while aberrant methylation patterns and histone modifications reflect epigenetic changes. Gene expression changes manifest either as a direct consequence of genetic and epigenetic alterations or as reactive changes and downstream effects. Furthermore, transcription patterns are also mediated by noncoding RNAs such as microRNAs (miRNAs), which can be deregulated by the aforementioned genetic and epigenetic alterations. The global profiling of each omics dimension represents a remarkable technological and bioinformatic achievement. However, the integration of these individual dimensions must be pursued in order to provide a comprehensive view of the impact of gene disruption in SqCC. Hence, there is a growing need to merge these multiple dimensions of data to identify concerted and complementary alterations that lead to the perturbation of oncogenic pathways and gene networks.

2. Multidimensional Analysis of Cancer Genomes

2.1. Genomic Alterations in Cancer

Genome destabilization is one of the hallmarks of cancer and is reflected by the accumulation of multiple genetic alterations such as chromosomal translocation, DNA copy number alteration, and sequence mutation [1]. Chromosomal translocation has been shown activate oncogenes by gene fusion [24]. Segmental duplication and amplification leads to increased gene dosage and, often, inappropriate expression of oncogenes [5] (Figure 1). Deletion leads to loss of tumor suppressor function through either haploinsufficiency or two-hit inactivation of functional alleles [6, 7]. Examples of such two-hit mechanisms are homozygous deletion or a combination of deletion and gene mutation. DNA mutation can lead to a variety of effects, such as constitutive gene activation or inactivation. A variety of technology platforms have been developed that are tailored to the detection of specific types of genomic alterations. These technologies are summarized in Table 1.

Figure 1
Mechanisms of DNA copy number alteration. (a) Segmental gains and losses can lead to DNA copy number alterations. (b) Allelic imbalance and loss of heterozygosity (LOH) can arise from a deletion event or gene conversion during mitosis.
Table 1
Genome-wide methods for identifying genetic alterations.

2.2. Epigenomics of Cancer

Epigenetics is the study of heritable chromosomal changes that influence transcription but do not directly alter the DNA sequence [24]. Mechanisms of epigenetic gene regulation include DNA methylation and histone modification. Altered epigenetic regulation in cancer includes hypo- and hypermethylation of genes, which can lead to increased genomic instability and the activation of oncogenes or the silencing of tumor suppressor genes, respectively. Similarly, the modification of histones can modulate chromatin structure and accessibility (Figure 2). The genome-wide alignment of epigenetic aberrations with genetic alterations can lead to the identification of genes disrupted in both alleles. For example, in the two-hit model one allele could be lost to deletion, while the other copy is silenced by hypermethylation. These events can in turn lead to changes in gene expression levels [2527]. A wide range of methodologies exists for the determination of methylation status, which rely on bisulfite conversion of cytosines [2832], immunoprecipitation of methylated DNA [33, 34], or the sensitivity of endonucleases to DNA methylation [35, 36]. The technologies in methylome analysis are summarized in Table 2 [27]. Histone modification analysis is complex due to the variety of modifications and the different residues being modified. Common methods of assessment such as ChIP-chip and ChIP-seq involve immunoprecipitation using antibodies against specific types of modification and are the subject of recent review articles [3739].

Figure 2
Mechanisms of epigenetic gene silencing. Unmethylated DNA is accessible to activator proteins and transcription factors (TF) enabling transcription. DNA methylation by DNA methyl transferases (DNMT) causes steric inhibition of transcription complexes ...
Table 2
Techniques for genome-wide analysis of the methylome.

2.3. Gene Expression Profiling

The downstream effect of genomic and epigenomic alterations is the dysregulation of gene expression. Global gene expression profiling has been instrumental in both disease classification and cancer gene discovery [4954], as well as in biomarker discovery in a wide range of cancers [5557]. The evolution of gene expression profiling technologies and their applications to cancer biology is well documented in the literature [58, 59]. While microarrays are widely used for expression profiling, sequence-based approaches such as serial analysis of gene expression (SAGE) present a digital alternative to measuring transcript abundance [60]. More recently, the emergence of massively parallel and next-generation sequencing platforms has revolutionized whole transcriptome analysis [2023]. Expression changes are not limited to protein coding genes; alterations in miRNA levels have been well documented in various cancer types, discussed below.

2.4. Noncoding RNAs

Approximately 90% of the human genome is transcribed, with only a small fraction of these transcripts representing protein coding mRNAs [6164]. The remaining transcripts are comprised of a wide range of noncoding RNAs (ncRNAs) including ribosomal RNAs (rRNAs), transfer RNAs (tRNAs), miRNAs, and a recently described class, long noncoding RNAs (lncRNAs) [65].

MicroRNAs are small ~22 nucleotide (nt) RNAs involved in posttranscriptional silencing of mRNA targets [66]. These regulatory RNAs exhibit an enormous influence on most fundamental biological processes, altering the expression of proteins by inhibiting translation or promoting mRNA degradation [67]. Aberrant miRNA expression has been linked to a range of diseases, including cancer progression and prognosis [68, 69]. Many of the mechanisms described to alter normal gene expression in cancer can also influence the expression of miRNAs. For instance, the gain or loss of a specific miRNA can function as either an oncogene or a tumor suppressor [7072], and mutations in miRNA sequences or miRNA processing machinery can have a tremendous impact on miRNA regulatory function [73]. Intriguingly, the expression of miRNAs can also be regulated by epigenetic mechanisms [74], while in turn, miRNA expression can modulate epigenetic regulation by targeting enzymes responsible for histone modification and DNA methylation [75, 76].

More recently, lncRNAs have been described to function as epigenetic regulators of transcription, chromatin remodeling and cellular development [65, 77, 78]. While the extent of their involvement in tumorigenesis is unknown, the dysregulation of lncRNAs may prove to be yet another level of complexity in the cancer genomic landscape.

In combination with genomic, epigenomic, and transcriptomic alterations, the capacity of ncRNAs to influence the expression of a range of biological processes highlights the need to merge the multiple dimensions of whole genome analysis. Integrative genomics is the response to this requirement as highlighted below.

2.5. Integrative Genomics

Until recently, the study of cancer genomes, epigenomes, and transcriptomes has largely been done in a solitary manner. With technologies to assess these different dimensions becoming more accessible (Figure 3), the integration of these diverse data dimensions in parallel is the next logical step. In fact, large-scale initiatives, such as those led by The Cancer Genome Atlas (TCGA) Research Network (, are proposing the comprehensive characterization of genomic, epigenomic, and transcriptomic alterations for a multitude of cancer types.

Figure 3
Multidimensional omics data integration using SIGMA2 software. Combined genetic, epigenetic and gene expression analysis of cancer samples facilitates identification of oncogenes and tumor suppressor genes which are concertedly disrupted. (a) Examples ...

While the majority of previous integrative studies have focused on correlating copy number alterations with gene expression changes, there have been a few more recent studies which have incorporated the epigenomic dimension as well [7983]. Moreover, from these studies, it is clear that both quantitative and qualitative benefits are reaped when employing a Multidimensional approach. For example, the abilities to (i) associate more of the observed aberrant gene expression to genetic and epigenetic alterations (ii) identify complementary alterations in different samples which lead to similar downstream effects, and (iii) elucidate complex disruption patterns of both known and novel signaling pathways are some of the key findings that have been made. However, a consequence of assessing the cancer cell at a high resolution is the generation of copious amounts of data and the subsequent need for specialized bioinformatic tools [84]. As a result, there have been a number of recently developed tools to address this need. Table 3 lists these tools and where they can be obtained.

Table 3
Software for integrative analysis of Multidimensional omics data.

3. Applying Integrative Genomics to Squamous Cell Carcinoma

The unique biology of SqCCs arising from different tissues is reflected in their underlying genetic variability. Here we examine the use of multiple dimensions of omics data in elucidating the underlying genetic features of three common types of SqCCs. (1) Oral SqCC illustrates how elevated genomic instability may predispose early lesions to cancer progression. (2) Lung SqCC has recently been found to harbor critical cell lineage-specific genetic alterations. (3) Finally, skin SqCC demonstrates how a single pathway can be disrupted at multiple nodes, and specific pathways are dysregulated in cancer subtypes. These inherent tissue-specific differences in SqCCs may yield novel genes and pathways suitable for tailoring cancer diagnostics and therapy. The use of Multidimensional, genome wide analysis will be instrumental in facilitating these discoveries.

3.1. Genetic Instability in Oral Squamous Cell Carcinoma

The majority of oral malignancies in the upper aerodigestive tract are SqCCs [93]. The strongest etiological factor for oral carcinogenesis is tobacco smoke, while human papillomavirus (HPV) infection has been frequently detected in nonsmoker and younger oral squamous cell carcinoma (OSCC) patients [9397]. Differences in the pattern of genetic alterations suggest that HPV-positive oral cancers may represent a distinct disease entity that develops via a different genetic pathway [98].

As in other SqCCs, the evolution of OSCC is known to result from the acquisition of multiple genetic events targeting different genes and molecular pathways [99]. Genomic instability increases progressively from hyperplasia through various stages of dysplasia to invasive carcinoma [100]. Although specific genetic alterations have been frequently detected in early stage dysplasias, it is believed that it is the accumulation of genomic instability, rather than the sequence of specific events, that determines oral carcinogenesis [100, 101]. Thus, examining oral premalignant lesions (OPLs) would allow the identification of early genetic events that may be masked by increased genomic instability in late stage tumors and, as such, could potentially identify biomarkers for predicting OPLs that will progress to cancer. Previous studies have identified several loci, including multiple regions on chromosome arm 3p, such as the 3p14 locus that harbors FHIT (Fragile Histidine Triad), to be commonly deleted in oral dysplasias [102104]. However, assaying only several loci does not provide sufficient predictive power for progression. Whole-genome tiling-path array comparative genomic hybridization (aCGH) facilitated comprehensive mapping of genetic alterations in premalignant and malignant oral tissues. It was determined that low-grade dysplasias that would progress had the genomic patterns that resembled those observed in high-grade dysplasias (Figure 4), exhibiting increased genomic instability before phenotypic or histological appearances. In contrast, these genetic alterations were rare in benign low-grade dysplasias that did not progress [101, 105]. Another frequent genomic alteration present in oral dysplasias that have a high risk of progression was DNA amplification, which is often an indicator of tumor aggressiveness. Specifically, coamplification of the oncogenes EGFR and CCND1 was observed [101, 105, 106].

Figure 4
Whole-genome tiling-path array profile of an oral low-grade dysplasia. Normalized log2 signal intensity ratios were plotted using SIGMA software [85, 86]. Cytoband pattern corresponding to the data points was drawn to the left of each data plot. The ...

This pattern of genomic instability was informative, but it is useful to derive the mechanism of cancer progression. To decipher what pathways were disrupted and what genes were involved, the aCGH data was overlaid with publically available expression data. It was discovered that the majority of genes altered at the genomic and transcriptomic level converged into a single pathway, the FGF signalling pathway. Oral cancer is therefore an example of the importance of considering the downstream effect of genomic alterations and determination of biochemical pathways affected. Pathways may be affected early or late, but the ultimate phenotype may be redundant.

3.2. Lineage-Specific Genetic Features in Lung Cancer

Lung cancer is divided into two major categories, small cell lung cancer (SCLC) and nonsmall cell lung cancer (NSCLC). The latter accounts for 85% of lung cancer cases and is further subdivided into adenocarcinoma (AC), squamous cell carcinoma (SqCC), and large cell carcinoma (LCC). While the prevalence of AC is rising, SqCC accounts for approximately 30% of lung cancer cases [107, 108].

The differential response to specific therapy highlights the importance of treating lung cancer subtypes as genetically distinct. For example, Gefitinib and Erlotinib target the tyrosine kinase surface receptor, EGFR, which was found to be overexpressed in at least 50% of lung cancers [109]. Strikingly, clinical trials revealed that most patients with NSCLC had moderate to no drug response, except only a subset of patients that were highly responsive [110113]. The responders had mutations in the catalytic domain of EGFR, which resulted in increased drug efficacy [114]. Specifically, EGFR mutations and drug sensitivity were associated with the AC subtype, never-smoking status, Asian ethnicity, and female gender [110]. In another example, drug response variability was seen with the advent of the thymidylate synthase (TS) inhibitor, Pemetrexed. Pemetrexed exhibits a higher efficacy in AC compared to SqCC, likely due to the generally higher levels of TS expression in SqCC [115117]. These clinical results have provided an impetus to delineate the different genetic mechanisms governing lung cancer subtypes, in order to tailor treatment for SqCC and AC.

Evidence from lung tumors is rapidly accumulating to indicate not only that are AC and SqCC composed of different genomic backgrounds (Figure 5), but also that they arise from the disruption of different biochemical pathways. Two key lineage-specific genetic differences between SqCC and AC were recently discovered using integrative genomics technologies. Both genes appear to be specific to the SqCC lineage and were found to be highly amplified. These genes were SOX2, likely involved in squamous pluripotency and differentiation [118], and BRF2, a RNA polymerase III transcription initiation factor controlling cell growth [119]. These discoveries suggest that SqCC and AC are genetically distinct.

Figure 5
Genome-wide comparison of lung adenocarcinoma (AC) and squamous cell carcinoma (SqCC). Affymetrix SNP 6.0 data for 11 SqCC and 49 AC cell lines were downloaded from the Wellcome Trust Sanger Cancer Genome Project. Data were analyzed against a pool of ...

3.3. Genes and Pathways Disrupted in Squamous Cell Carcinoma of the Skin

Like lung cancer, skin cancer is divided into two types: melanoma skin cancer and nonmelanoma skin cancer (NMSC). Skin SqCC is a subtype of nonmelanoma skin cancer (NMSC), a classification that also includes basal cell carcinoma (BCC). The standard treatment option for NMSC is surgical biopsy, which has been applied frequently and successfully without recurrence [120]. Occasionally, NMSC develops to an advanced stage, and in 3%–5% of cases the tumor metastasizes, lowering the 5-year survival rate to 14%–39% [121]. Advanced cases of NMSC are not always treatable by biopsy alone [120]. Subsequent treatment options include chemotherapy, radiation therapy, or a combination of surgery and radiation [120, 121]. To date, chemotherapeutics such as cisplatin, 5-Fluor-Uracil, Paclitaxel, and combinations have been utilized with limited success [121]. Knowledge of the molecular mechanisms controlling NMSC tumors holds promise in improving treatment.

SqCC and BCC should be regarded as genetically distinct as different biological pathways are disrupted in these disease types [122]. The pathogenesis of SqCC is complex and dependent on many intrinsic and extrinsic factors. It is generally recognized that the most important extrinsic factor is UV sunlight exposure, as incidence of squamous cell carcinoma increases with lifetime UV exposure [123]. Using previously unexposed human skin, exposure to UV was shown to result in a missense point mutation with a UV signature in one TP53 allele, and the remaining allele is deleted [124]. SqCC undergoes the inactivation of multiple tumor suppressor genes, namely, TP53 which is inactivated in 90% of all precancerous lesions and invasive tumors, and also P16 and P14 [125, 126]. TP53 is also mutated in BCC; however, the mutation rate decreases from 90% to 50% [127129]. Broader examination of subtype-specific changes indicates that SqCC and BCC accrue alterations of different biochemical pathways.

In SqCC, deregulation of the PI3K/AKT signaling pathway is common. This pathway has been demonstrated to control cellular functions such as apoptosis, cell proliferation, and cell growth in isogenic cell lines [121, 130]. Mechanistically, the most common mechanisms of alteration are constitutive growth factor receptor activation, PI3K amplification or mutation, AKT amplification or mutation, and PTEN inactivation (Figure 6(a)) [121]. The main affected pathway in BCC is the sonic hedgehog (Shh) signaling pathway. In skin, this pathway regulates the development of follicles and sebaceous glands, as well as maintains stem cell populations [131]. In tumors the patched (PTCH) or smoothened (Smo) genes have been found to be most commonly altered, with mutation rates of 30%–60%. PTCH is inactivated most commonly by chromosomal deletion or by mutation [131, 132], while mutations in sonic hedgehog (Shh) and Smo have also been documented. In addition to genomic alterations, expression level analysis has revealed increased levels of PTCH and hedgehog interacting protein (HIP) mRNA, adding a dimension of change (Figure 6(b)). Much like oral cancer, both SqCC and BCC experience dysregulation of a certain pathway, via disruption of multiple component genes.

Figure 6
Major pathways affected in NMSC. (a) SqCC undergoes frequent alterations to the PI3K/AKT signaling pathway. (b) BCC undergoes frequent alterations to the sonic hedgehog pathway. Various pathway components affected are highlighted in red.

SqCC is associated with significant chromosomal aberrations at all stages of progression (reviewed in [133, 134]). In general, SqCC has increased genomic instability with 25%–90% of tumors demonstrating DNA aneuploidy. In contrast, BCC genomes are reasonably stable demonstrating 9%–40% aneuploidy. Early studies examined the extent of LOH in SqCC, finding it to be both diverse and widespread. Frequent regions of LOH were determined at 13q (46%), 9p (41%), 17p (33%), 17q (33%), and 3p (23%) [135]. In addition, SqCC has a range of other chromosomal alterations, including gain of chromosomes 3q, 8q, 14q, and 17q and deletion of chromosomes 8p, 9p, 17p, and 18q [133]. In BCC, loss of genetic material was found to be confined to 9q22.3, the locus of the PTCH tumor suppressor gene [136138]. A more complete picture of the genes and pathways disrupted in SqCC development could be obtained if these genomic data were integrated with epigenetic and transcriptomic data sets. However, the literature on genome-wide scans for epigenetic alterations and transcriptional changes in NMSC is scarce; global approaches will be crucial to identifying novel genes and pathways involved in the carcinogenesis of NMSC.

4. Squamous Cell Carcinoma and Integrative Genomics: Present and Future

While genetic, epigenetic, and transcriptional changes are associated with disease, their pathological impact is ultimately held at the levels of protein, cell, tissue, and organismal functions. It is widely believed that integrative phenomics—high throughput phenotyping of any type—will reveal different cancer subtypes with distinct biochemical and biological profiles (Figure 7). After transcriptomics, proteomics and metabolomics were the next types of phenomics to be developed [139].

Figure 7
The integrated network of genome-wide analyses comprising the cancer omics landscape. Phenomics or phenotypic effects are the direct consequence of the perturbations of genes and pathways which could be traced to genetic and epigenetic alterations when ...

The proteome is the universe of proteins, and proteomics is the study of the structure, regulation, and function of the proteome. The most obvious types of knowledge to be gained are the functional consequences of differential protein expression, profiles of proteins and their posttranslational modification (phosphorylation, ubiquitination, acetylation, palmitoylation, polysialylation, proteolytic cleavage, and dozens more), and identification of protein-protein interactions. Recent reviews address different aspects of cancer proteomics [139142]. The most common proteomics approach has been the coupling of two-dimensional gel electrophoresis with mass spectrometry (MS). This gel methodology can resolve up to 11000 spots but more commonly separates approximately 2000–4000. 2D fluorescence difference gel electrophoresis (2-D DIGE) uses ultrasensitive fluorescent dyes to label multiple samples in different colors, thus allowing the relative quantification of the same proteins from different samples. More recently, gel-free proteomic techniques have been developed, such as multidimensional protein identification technology (MudPIT). There have been many recent developments in MS sample preparation, methodologies, and data analysis [143]. Another large-scale approach to detect proteins is antibody microarrays [144]. The most common techniques used to discover protein-protein interactions are affinity purification coupled with MS and yeast two-hybrid analysis [145]. Among the most important new applications of proteomics are those defining the universe of posttranslational modifications (e.g., related to signaling or metabolism) and conducting functional screens of gene (e.g., using shRNA) and compound libraries. Other recent studies have begun to yield candidate biomarkers and suggest therapeutic pathways.

Metabolomics is the large-scale identification and quantification of metabolites [146]. These include sugars, salts, amino acids, peptides, lipids, acids, bases, steroid hormones, and so forth. There are almost 7000 known endogenous metabolites from 52 classes of compounds [147], but there are likely many more to be discovered. Metabolites are not only the products of cellular metabolism but also signaling molecules involved in the regulation of physiological states (e.g., feedback regulation, homeostasis). Thus, metabolomics may not only lead to the discovery of new biomarkers, but is also likely to reveal altered biochemical and physiological states. That would, in turn, suggest biochemical pathways that could be targeted therapeutically, and cellular assays to screen drugs or biologicals (e.g., siRNA, humanized antibodies). The most common approaches for global metabolomic profiling involve different separation technologies—such as liquid/gas chromatography and capillary electrophoresis—coupled with detection and identification using MS or nuclear magnetic resonance spectrometry (NMR) [148]. The data generated in this field is complex, and there is intense focus on the development of statistical methods [149] and database resources [150]. Oncology is one of the leading applications of metabolomics, both in clinical [151] and animal studies [152]. A major area of recent interest in cancer metabolomics is that related to the Warburg effect—the switch from oxidative phosphorylation to glycolysis that is associated with many cancers [153], including OSCC [154]. The state of the art in cancer metabolomics is illustrated by a prostate study that profiled 1126 metabolites across 262 clinical samples from 42 tissues and 110 each of urine and plasma [155]. The resulting profiles distinguished pathological subtypes (as well as the benign condition) and identified sarcosine as a metabolite that is highly increased with prostate cancer progression.

Many areas of proteomics and metabolomics have unique methodological requirements and are considered subdisciplines—for example, glycomics, lipidomics, spliceosomics, phosphoproteomics, and ubiquinomics. A major challenge for human studies is that available tissues are generally limited to biopsy samples, circulating blood cells (including purified lymphocytes, hematopoietic stem cells, platelets, etc.), and body fluids [142]. Recently, methodologies have been developed to allow analysis of not only fresh and frozen tissues but also formalin-fixed and paraffin-embedded tissue. Notably, workflows are being developed to collect and process diverse clinical samples for integrative omics studies [140].

In conclusion, from the early studies integrating genomic and epigenomic data, it is apparent that much can be gained when a multifaceted approach is employed. With multiple large-scale initiatives prioritizing this style of analysis on a diverse spectrum of tumor types, and with the continuing evolution of high throughput technologies to measure additional dimensions, the ability to perform bona fide molecular systems biology in clinical specimens may finally be in sight.


The authors wish to thank Emily Vucic and Ian Wilson for their useful comments. This work was supported by funds from the Canadian Institutes for Health Research (MOP 86731, MOP 77903), Canadian Cancer Society (CCS20485), NCI Early Detection Research Network (EDRN) (5U01 CA84971-10), and the Canary Foundation. C.E. Alvarez was supported by the United States National Institutes of Health (HG004663). R. Chari and I.F.L. Tsui were supported by scholarships from the Canadian Institutes for Health Research and the Michael Smith Foundation for Health Research. E. Gibb and K. Enfield contributed equally.


1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57–70. [PubMed]
2. de Klein A. Oncogene activation by chromosomal rearrangement in chronic myelocytic leukemia. Mutation Research. 1987;186(2):161–172. [PubMed]
3. Haluska FG, Tsujimoto Y, Croce CM. Oncogene activation by chromosome translocation in human malignancy. Annual Review of Genetics. 1987;21:321–345. [PubMed]
4. Dessars B, de Raeve LE, Housni HE, et al. Chromosomal translocations as a mechanism of BRAF activation in two cases of large congenital melanocytic nevi. Journal of Investigative Dermatology. 2007;127(6):1468–1470. [PubMed]
5. Lockwood WW, Chari R, Coe BP, et al. DNA amplification is a ubiquitous mechanism of oncogene activation in lung and other cancers. Oncogene. 2008;27(33):4615–4624. [PMC free article] [PubMed]
6. Albertson DG, Collins C, McCormick F, Gray JW. Chromosome aberrations in solid tumors. Nature Genetics. 2003;34(4):369–376. [PubMed]
7. Dong JT. Chromosomal deletions and tumor suppressor genes in prostate cancer. Cancer and Metastasis Reviews. 2001;20(3-4):173–193. [PubMed]
8. Schröck E, du Manoir S, Veldman T, et al. Multicolor spectral karyotyping of human chromosomes. Science. 1996;273(5274):494–497. [PubMed]
9. Fauth C, Speicher MR. Classifying by colors: FISH-based genome analysis. Cytogenetics and Cell Genetics. 2001;93(1-2):1–10. [PubMed]
10. Speicher MR, Ward DC. The coloring of cytogenetics. Nature Medicine. 1996;2(9):1046–1048. [PubMed]
11. Lichter P. Multicolor fishing: what’s the catch? Trends in Genetics. 1997;13(12):475–479. [PubMed]
12. Levsky JM, Singer RH. Fluorescence in situ hybridization: past, present and future. Journal of Cell Science. 2003;116(14):2833–2838. [PubMed]
13. Pinkel D, Segraves R, Sudar D, et al. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nature Genetics. 1998;20(2):207–211. [PubMed]
14. Ishkanian AS, Malloff CA, Watson SK, et al. A tiling resolution DNA microarray with complete coverage of the human genome. Nature Genetics. 2004;36(3):299–303. [PubMed]
15. Parrett TJ, Yan H. Digital karyotyping technology: exploring the cancer genome. Expert Review of Molecular Diagnostics. 2005;5(6):917–925. [PubMed]
16. Salani R, Chang CL, Cope L, Wang TL. Digital karyotyping: an update of its applications in cancer. Molecular Diagnosis and Therapy. 2006;10(4):231–237. [PubMed]
17. Shih IeM, Wang TL. Apply innovative technologies to explore cancer genome. Current Opinion in Oncology. 2005;17(1):33–38. [PubMed]
18. Hampton GM, Larson AA, Baergen RN, Sommers RL, Kern S, Cavenee WK. Simultaneous assessment of loss of heterozygosity at multiple microsatellite loci using semi-automated fluorescence-based detection: subregional mapping of chromosome 4 in cervical carcinoma. Proceedings of the National Academy of Sciences of the United States of America. 1996;93(13):6704–6705. [PubMed]
19. Beroukhim R, Lin M, Park Y, et al. Inferring loss-of-heterozygosity from unpaired tumors using high-density oligonucleotide SNP arrays. PLoS Computational Biology. 2006;2(5, article e41) [PMC free article] [PubMed]
20. Schuster SC. Next-generation sequencing transforms today’s biology. Nature Methods. 2008;5(1):16–18. [PubMed]
21. Mardis ER. The impact of next-generation sequencing technology on genetics. Trends in Genetics. 2008;24(3):133–141. [PubMed]
22. Rothberg JM, Leamon JH. The development and impact of 454 sequencing. Nature Biotechnology. 2008;26(10):1117–1124. [PubMed]
23. Choi M, Scholl UI, Ji W, et al. Genetic diagnosis by whole exome capture and massively parallel DNA sequencing. Proceedings of the National Academy of Sciences of the United States of America. 2009;106(45):19096–19101. [PubMed]
24. Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis. 2009;31(1):27–36. [PMC free article] [PubMed]
25. Shaw RJ, Hall GL, Lowe D, et al. The role of pyrosequencing in head and neck cancer epigenetics: correlation of quantitative methylation data with gene expression. Archives of Otolaryngology—Head and Neck Surgery. 2008;134(3):251–256. [PubMed]
26. Vucic EA, Wilson IM, Campbell JM, Lam WL. Methylation analysis by DNA immunoprecipitation (MeDIP) Methods in Molecular Biology. 2009;556:141–153. [PubMed]
27. Thu KL, Vucic EA, Kennett JY, et al. Methylated DNA immunoprecipitation. Journal of Visualized Experiments. 2009;(23, article 935) [PMC free article] [PubMed]
28. Frommer M, McDonald LE, Millar DS, et al. A genomic sequencing protocol that yields a positive display of 5- methylcytosine residues in individual DNA strands. Proceedings of the National Academy of Sciences of the United States of America. 1992;89(5):1827–1831. [PubMed]
29. Clark SJ, Harrison J, Paul CL, Frommer M. High sensitivity mapping of methylated cytosines. Nucleic Acids Research. 1994;22(15):2990–2997. [PMC free article] [PubMed]
30. Chung CAB, Boyd VL, McKernan KJ, et al. Whole methylome analysis by ultra-deep sequencing using two-base encoding. PLoS ONE. 2010;5(2, article e9320) [PMC free article] [PubMed]
31. Zilberman D, Henikoff S. Genome-wide analysis of DNA methylation patterns. Development. 2007;134(22):3959–3965. [PubMed]
32. Beier V, Mund C, Hoheisel JD. Monitoring methylation changes in cancer. Advances in Biochemical Engineering/Biotechnology. 2007;104:1–11. [PubMed]
33. Keshet I, Schlesinger Y, Farkash S, et al. Evidence for an instructive mechanism of de novo methylation in cancer cells. Nature Genetics. 2006;38(2):149–153. [PubMed]
34. Weber M, Davies JJ, Wittig D, et al. Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nature Genetics. 2005;37(8):853–862. [PubMed]
35. Nouzova M, Holtan N, Oshiro MM, et al. Epigenomic changes during leukemia cell differentiation: analysis of histone acetylation and cytosine methylation using CpG island microarrays. Journal of Pharmacology and Experimental Therapeutics. 2004;311(3):968–981. [PubMed]
36. Lippman Z, Gendrel AV, Colot V, Martienssen R. Profiling DNA methylation pattern using genomic tiling microarrays. Nature Methods. 2005;2(3):219–224. [PubMed]
37. Wu J, Smith LT, Plass C, Huang THM. ChIP-chip comes of age for genome-wide functional analysis. Cancer Research. 2006;66(14):6899–6902. [PubMed]
38. Park PJ. ChIP-seq: advantages and challenges of a maturing technology. Nature Reviews Genetics. 2009;10(10):669–680. [PMC free article] [PubMed]
39. Barski A, Zhao K. Genomic location analysis by ChIP-seq. Journal of Cellular Biochemistry. 2009;107(1):11–18. [PubMed]
40. Lister R, Pelizzola M, Dowen RH, et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature. 2009;462(7271):315–322. [PMC free article] [PubMed]
41. Bibikova M, Lin Z, Zhou L, et al. High-throughput DNA methylation profiling using universal bead arrays. Genome Research. 2006;16(3):383–393. [PubMed]
42. Bailey VJ, Easwaran H, Zhang Y, et al. MS-qFRET: a quantum dot-based method for analysis of DNA methylation. Genome Research. 2009;19(8):1455–1461. [PubMed]
43. Ball MP, Li JB, Gao Y, et al. Targeted and genome-scale strategies reveal gene-body methylation signatures in human cells. Nature Biotechnology. 2009;27(4):361–368. [PMC free article] [PubMed]
44. Shen Y, Fouse SD, Fan G. Genome-wide DNA methylation profiling: the mDIP-chip technology. Methods in Molecular Biology. 2009;568:203–216. [PubMed]
45. Rauch T, Pfeifer GP. Methylated-CpG island recovery assay: a new technique for the rapid detection of methylated-CpG islands in cancer. Laboratory Investigation. 2005;85(9):1172–1180. [PubMed]
46. Irizarry RA, Ladd-Acosta C, Carvalho B, et al. Comprehensive high-throughput arrays for relative methylation (CHARM) Genome Research. 2008;18(5):780–790. [PubMed]
47. Khulan B, Thompson RF, Ye K, et al. Comparative isoschizomer profiling of cytosine methylation: the HELP assay. Genome Research. 2006;16(8):1046–1055. [PubMed]
48. Costello JF, Hong C, Plass C, Smiraglia DJ. Restriction landmark genomic scanning: analysis of CpG islands in genomes by 2D gel electrophoresis. Methods in Molecular Biology. 2009;507:131–148. [PubMed]
49. Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999;286(5439):531–527. [PubMed]
50. Perou CM, Sørile T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–752. [PubMed]
51. Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proceedings of the National Academy of Sciences of the United States of America. 2001;98(19):10869–10874. [PubMed]
52. Bittner M, Meltzer P, Chen Y, et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature. 2000;406(6795):536–540. [PubMed]
53. Garber ME, Troyanskaya OG, Schluens K, et al. Diversity of gene expression in adenocarcinoma of the lung. Proceedings of the National Academy of Sciences of the United States of America. 2001;98(24):13784–13789. [PubMed]
54. Bhattacharjee A, Richards WG, Staunton J, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proceedings of the National Academy of Sciences of the United States of America. 2001;98(24):13790–13795. [PubMed]
55. Alevizos I, Mahadevappa M, Zhang X, et al. Oral cancer in vivo gene expression profiling assisted by laser capture microdissection and microarray analysis. Oncogene. 2001;20(43):6196–6204. [PubMed]
56. Clark EA, Golub TR, Lander ES, Hynes RO. Genomic analysis of metastasis reveals an essential role for RhoC. Nature. 2000;406(6795):532–535. [PubMed]
57. Hegde P, Qi R, Gaspard R, et al. Identification of tumor markers in models of human colorectal cancer using a 19,200-element complementary DNA microarray. Cancer Research. 2001;61(21):7792–7797. [PubMed]
58. Macgregor PF, Squire JA. Application of microarrays to the analysis of gene expression in cancer. Clinical Chemistry. 2002;48(8):1170–1177. [PubMed]
59. Coe BP, Chari R, Lockwood WW, Lam WL. Evolving strategies for global gene expression analysis of cancer. Journal of Cellular Physiology. 2008;217(3):590–597. [PubMed]
60. Velculescu VE, Zhang L, Vogelstein B, Kinzler KW. Serial analysis of gene expression. Science. 1995;270(5235):484–487. [PubMed]
61. Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nature Methods. 2008;5(7):621–628. [PubMed]
62. Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nature Genetics. 2008;40(12):1413–1415. [PubMed]
63. Wilhelm BT, Marguerat S, Watt S, et al. Dynamic repertoire of a eukaryotic transcriptome surveyed at single-nucleotide resolution. Nature. 2008;453(7199):1239–1243. [PubMed]
64. Djebali S, Kapranov P, Foissac S, et al. Efficient targeted transcript discovery via array-based normalization of RACE libraries. Nature Methods. 2008;5(7):629–635. [PMC free article] [PubMed]
65. Costa FF. Non-coding RNAs: meet thy masters. BioEssays. 2010;32(7):599–608. [PubMed]
66. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–297. [PubMed]
67. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nature Reviews Genetics. 2008;9(2):102–114. [PubMed]
68. Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nature Genetics. 2007;39(5):673–677. [PubMed]
69. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nature Reviews Cancer. 2006;6(11):857–866. [PubMed]
70. Kent OA, Mendell JT. A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes. Oncogene. 2006;25(46):6188–6196. [PubMed]
71. Esquela-Kerscher A, Slack FJ. Oncomirs—microRNAs with a role in cancer. Nature Reviews Cancer. 2006;6(4):259–269. [PubMed]
72. Starczynowski DT, Kuchenbauer F, Argiropoulos B, et al. Identification of miR-145 and miR-146a as mediators of the 5q-syndrome phenotype. Nature Medicine. 2010;16(1):49–58. [PubMed]
73. Ryan BM, Robles AI, Harris CC. Genetic variation in microRNA networks: the implications for cancer research. Nature Reviews Cancer. 2010;10(6):389–402. [PMC free article] [PubMed]
74. Saito Y, Jones PA. Epigenetic activation of tumor suppressor microRNAs in human cancer cells. Cell Cycle. 2006;5(19):2220–2222. [PubMed]
75. Fabbri M, Garzon R, Cimmino A, et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proceedings of the National Academy of Sciences of the United States of America. 2007;104(40):15805–15810. [PubMed]
76. Friedman JM, Liang G, Liu CC, et al. The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. Cancer Research. 2009;69(6):2623–2629. [PubMed]
77. Caley DP, Pink RC, Trujillano D, Carter DRF. Long noncoding RNAs, chromatin, and development. TheScientificWorldJournal. 2010;10:90–102. [PubMed]
78. Malecová B, Morris KV. Transcriptional gene silencing through epigenetic changes mediated by non-coding RNAs. Current Opinion in Molecular Therapeutics. 2010;12(2):214–222. [PMC free article] [PubMed]
79. Gray JW, Collins C. Genome changes and gene expression in human solid tumors. Carcinogenesis. 2000;21(3):443–452. [PubMed]
80. Chari R, Coe BP, Vucic EA, Lockwood WW, Lam WL. An integrative multi-dimensional genetic and epigenetic strategy to identify aberrant genes and pathways in cancer. BMC Systems Biology. 2010;4, article 67 [PMC free article] [PubMed]
81. McLendon R, Friedman A, Bigner D, et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061–1068. [PMC free article] [PubMed]
82. Sadikovic B, Yoshimoto M, Chilton-MacNeill S, Thorner P, Squire JA, Zielenska M. Identification of interactive networks of gene expression associated with osteosarcoma oncogenesis by integrated molecular profiling. Human Molecular Genetics. 2009;18(11):1962–1975. [PubMed]
83. Chari R, Thu KL, Wilson IM, et al. Integrating the multiple dimensions of genomic and epigenomic landscapes of cancer. Cancer and Metastasis Reviews. 2010;29(1):73–93. [PMC free article] [PubMed]
84. Coe BP, Chari R, MacAulay C, Lam WL. FACADE: a fast and sensitive algorithm for the segmentation and calling of high resolution array CGH data. Nucleic Acids Research. 2010;38(15):e157–e157. [PMC free article] [PubMed]
85. Chari R, Lockwood WW, Coe BP, et al. SIGMA: a system for integrative genomic microarray analysis of cancer genomes. BMC Genomics. 2006;7, article 324 [PMC free article] [PubMed]
86. Chari R, Coe BP, Wedseltoft C, et al. SIGMA: a system for the integrative genomic multi-dimensional analysis of cancer genomes, epigenomes, and transcriptomes. BMC Bioinformatics. 2008;9, article 422 [PMC free article] [PubMed]
87. Conde L, Montaner D, Burguet-Castell J, et al. ISACGH: a web-based environment for the analysis of Array CGH and gene expression which includes functional profiling. Nucleic Acids Research. 2007;35:W81–W85. [PMC free article] [PubMed]
88. La Rosa P, Viara E, Hupé P, et al. VAMP: visualization and analysis of array-CGH, transcriptome and other molecular profiles. Bioinformatics. 2006;22(17):2066–2073. [PubMed]
89. Shinde K, Phatak M, Johannes FM, et al. Genomics Portals: integrative web-platform for mining genomics data. BMC Genomics. 2010;11(1, article 27) [PMC free article] [PubMed]
90. Lee M, Kim Y. CHESS (CgHExpreSS): a comprehensive analysis tool for the analysis of genomic alterations and their effecsts on the expression profile of the genome. BMC Bioinformatics. 2009;10, article 424 [PMC free article] [PubMed]
91. Lê Cao KA, González I, Déjean S. IntegrOmics: an R package to unravel relationships between two omics datasets. Bioinformatics. 2009;25(21):2855–2856. [PMC free article] [PubMed]
92. Gribov A, Sill M, Lück S, et al. SEURAT: visual analytics for the integrated analysis of microarray data. BMC Medical Genomics. 2010;3, article 21 [PMC free article] [PubMed]
93. Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncology. 2009;45(4-5):309–316. [PubMed]
94. Zhang L, Cheng X, Li YH, et al. High frequency of allelic loss in dysplastic lichenoid lesions. Laboratory Investigation. 2000;80(2):233–237. [PubMed]
95. Begum S, Cao D, Gillison M, Zahurak M, Westra WH. Tissue distribution of human papillomavirus 16 DNA integration in patients with tonsillar carcinoma. Clinical Cancer Research. 2005;11(16):5694–5699. [PubMed]
96. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. Journal of the National Cancer Institute. 2000;92(9):709–720. [PubMed]
97. Kreimer AR, Clifford GM, Snijders PJF, et al. HPV16 semiquantitative viral load and serologic biomarkers in oral and oropharyngeal squamous cell carcinomas. International Journal of Cancer. 2005;115(2):329–332. [PubMed]
98. Smeets SJ, Braakhuis BJM, Abbas S, et al. Genome-wide DNA copy number alterations in head and neck squamous cell carcinomas with or without oncogene-expressing human papillomavirus. Oncogene. 2006;25(17):2558–2564. [PubMed]
99. Mao L, Hong WK, Papadimitrakopoulou VA. Focus on head and neck cancer. Cancer Cell. 2004;5(4):311–316. [PubMed]
100. Hunter KD, Thurlow JK, Fleming J, et al. Divergent routes to oral cancer. Cancer Research. 2006;66(15):7405–7413. [PubMed]
101. Garnis C, Chari R, Buys TPH, et al. Genomic imbalances in precancerous tissues signal oral cancer risk. Molecular Cancer. 2009;8, article 50 [PMC free article] [PubMed]
102. Califano J, van der Riet P, Westra W, et al. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Research. 1996;56(11):2488–2492. [PubMed]
103. Tsui IF, Rosin MP, Zhang L, Ng RT, Lam WL. Multiple aberrations of chromosome 3p detected in oral premalignant lesions. Cancer Prevention Research. 2008;1(6):424–429. [PMC free article] [PubMed]
104. Rosin MP, Cheng X, Poh C, et al. Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clinical Cancer Research. 2000;6(2):357–362. [PubMed]
105. Tsui IFL, Poh CF, Garnis C, Rosin MP, Zhang L, Lam WL. Multiple pathways in the FGF signaling network are frequently deregulated by gene amplification in oral dysplasias. International Journal of Cancer. 2009;125(9):2219–2228. [PMC free article] [PubMed]
106. Myllykangas S, Böhling T, Knuutila S. Specificity, selection and significance of gene amplifications in cancer. Seminars in Cancer Biology. 2007;17(1):42–55. [PubMed]
107. Travis WD, Giroux DJ, Chansky K, et al. The IASLC lung cancer staging project: proposals for the inclusion of broncho-pulmonary carcinoid tumors in the forthcoming (seventh) edition of the TNM classification for lung cancer. Journal of Thoracic Oncology. 2008;3(11):1213–1223. [PubMed]
108. Sica G, Yoshizawa A, Sima CS, et al. A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage i tumors. American Journal of Surgical Pathology. 2010;34(8):1155–1162. [PubMed]
109. Rusch V, Baselga J, Cordon-Cardo C, et al. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Research. 1993;53(10):2379–2385. [PubMed]
110. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected] Journal of Clinical Oncology. 2003;21(12):2237–2246. [PubMed]
111. Jänne PA, Gurubhagavatula S, Yeap BY, et al. Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, ’Iressa’) on an expanded access study. Lung Cancer. 2004;44(2):221–230. [PubMed]
112. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. Journal of the American Medical Association. 2003;290(16):2149–2158. [PubMed]
113. Miller VA, Kris MG, Shah N, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. Journal of Clinical Oncology. 2004;22(6):1103–1109. [PubMed]
114. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung, cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497–1500. [PubMed]
115. Selvaggi G, Scagliotti GV. Histologic subtype in NSCLC: does it matter? Oncology. 2009;23(13):1133–1140. [PubMed]
116. Shin C, Chen VJ, Gossett LS, et al. Ly231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Research. 1997;57(6):1116–1123. [PubMed]
117. Ceppi P, Volante M, Saviozzi S, et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer. 2006;107(7):1589–1596. [PubMed]
118. Bass AJ, Watanabe H, Mermel CH, et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nature Genetics. 2009;41(11):1238–1242. [PMC free article] [PubMed]
119. Lockwood WW, Chari R, Coe BP, et al. Integrative genomic analyses identify BRF2 as a novel lineage-specific oncogene in lung squamous cell carcinoma. PLoS Medicine. 2010;7(7) Article ID e1000315. [PMC free article] [PubMed]
120. Kirby JS, Miller CJ. Intralesional chemotherapy for nonmelanoma skin cancer: a practical review. Journal of the American Academy of Dermatology. 2010;63(4):689–702. [PubMed]
121. Claerhout S, Verschooten L, van Kelst S, et al. Concomitant inhibition of AKT and autophagy is required for efficient cisplatin-induced apoptosis of metastatic skin carcinoma. International Journal of Cancer. 2010;127(12):2790–2803. [PubMed]
122. Dessinioti C, Antoniou C, Katsambas A, Stratigos AJ. Basal cell carcinoma: what’s new under the sun. Photochemistry and Photobiology. 2010;86(3):481–491. [PubMed]
123. Marks R. Squamous cell carcinoma. Lancet. 1996;347(9003):735–738. [PubMed]
124. Persson AE, Edstrom DW, Backvall H, et al. The mutagenic effect of ultraviolet-A1 on human skin demonstrated by sequencing the p53 gene in single keratinocytes. Photodermatology Photoimmunology and Photomedicine. 2002;18(6):287–293. [PubMed]
125. Brown VL, Harwood CA, Crook T, Cronin JG, Kelsell DR, Proby CM. p16 and p14 tumor suppressor genes are commonly inactivated in cutaneous squamous cell carcinoma. Journal of Investigative Dermatology. 2004;122(5):1284–1292. [PubMed]
126. Shulstad RM, Proper S. Squamous cell carcinoma: a review of etiology, pathogenesis, treatment, and variants. Journal of the Dermatology Nurses' Association. 2010;2(1):12–16.
127. Ziegler A, Jonason AS, Leffell DJ, et al. Sunburn and p53 in the onset of skin cancer. Nature. 1994;372(6508):773–776. [PubMed]
128. Benjamin CL, Ullrich SE, Kripke ML, Ananthaswamy HN. p53 tumor suppressor gene: a critical molecular target for UV induction and prevention of skin cancer. Photochemistry and Photobiology. 2008;84(1):55–62. [PubMed]
129. Elmets CA, Athar M. Targeting ornithine decarboxylase for the prevention of nonmelanoma skin cancer in humans. Cancer Prevention Research. 2010;3(1):8–11. [PMC free article] [PubMed]
130. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase-AKT pathway in human cancer. Nature Reviews Cancer. 2002;2(7):489–501. [PubMed]
131. Athar M, Tang X, Lee JL, Kopelovich L, Kim AL. Hedgehog signalling in skin development and cancer. Experimental Dermatology. 2006;15(9):667–677. [PubMed]
132. Koike C, Mizutani T, Ito T, et al. Introduction of wild-type patched gene suppresses the oncogenic potential of human squamous cell carcinoma cell lines including A431. Oncogene. 2002;21(17):2670–2678. [PubMed]
133. Ashton KJ, Carless MA, Griffiths LR. Cytogenetic alterations in nonmelanoma skin cancer: a review. Genes Chromosomes and Cancer. 2005;43(3):239–248. [PubMed]
134. Carless MA, Griffiths LR. Cytogenetics of melanoma and nonmelanoma skin cancer. Advances in Experimental Medicine and Biology. 2008;624:227–240. [PubMed]
135. Quinn AG, Sikkink S, Rees JL. Basal cell carcinomas and squamous cell carcinomas of human skin show distinct patterns of chromosome loss. Cancer Research. 1994;54(17):4756–4759. [PubMed]
136. Jin Y, Martins C, Jin C, et al. Nonrandom karyotypic features in squamous cell carcinomas of the skin. Genes Chromosomes and Cancer. 1999;26(4):295–303. [PubMed]
137. Jin Y, Martins C, Salemark L, et al. Nonrandom karyotypic features in basal cell carcinomas of the skin. Cancer Genetics and Cytogenetics. 2001;131(2):109–119. [PubMed]
138. Ashton KJ, Weinstein SR, Maguire DJ, Griffiths LR. Molecular cytogenetic analysis of basal cell carcinoma DNA using comparative genomic hybridization. Journal of Investigative Dermatology. 2001;117(3):683–686. [PubMed]
139. Tainsky MA. Genomic and proteomic biomarkers for cancer: a multitude of opportunities. Biochimica et Biophysica Acta. 2009;1796(2):176–193. [PMC free article] [PubMed]
140. Apweiler R, Aslanidis C, Deufel T, et al. Approaching clinical proteomics: current state and future fields of application in cellular proteomics. Cytometry A. 2009;75(10):816–832. [PubMed]
141. Peng XQ, Wang F, Geng X, Zhang WM. Current advances in tumor proteomics and candidate biomarkers for hepatic cancer. Expert Review of Proteomics. 2009;6(5):551–561. [PubMed]
142. Zamò A, Cecconi D. Proteomic analysis of lymphoid and haematopoietic neoplasms: there’s more than biomarker discovery. Journal of Proteomics. 2010;73(3):508–520. [PubMed]
143. Yates JR, Ruse CI, Nakorchevsky A. Proteomics by mass spectrometry: approaches, advances, and applications. Annual Review of Biomedical Engineering. 2009;11:49–79. [PubMed]
144. Wingren C, Borrebaeck CA. Antibody-based microarrays. Methods in Molecular Biology. 2009;509:57–84. [PubMed]
145. Figeys D. Mapping the human protein interactome. Cell Research. 2008;18(7):716–724. [PubMed]
146. Kaddurah-Daouk R, Kristal BS, Weinshilboum RM. Metabolomics: a global biochemical approach to drug response and disease. Annual Review of Pharmacology and Toxicology. 2008;48:653–683. [PubMed]
147. Wishart DS, Knox C, Guo AC, et al. HMDB: a knowledgebase for the human metabolome. Nucleic Acids Research. 2009;37(1):D603–D610. [PMC free article] [PubMed]
148. Lindon JC, Nicholson JK. Spectroscopic and statistical techniques for information recovery in metabonomics and metabolomics. Annual Review of Analytical Chemistry. 2008;1(1):45–69. [PubMed]
149. Issaq HJ, Van QN, Waybright TJ, Muschik GM, Veenstra TD. Analytical and statistical approaches to metabolomics research. Journal of Separation Science. 2009;32(13):2183–2199. [PubMed]
150. Go EP. Database resources in metabolomics: an overview. Journal of Neuroimmune Pharmacology. 2010;5(1):18–30. [PubMed]
151. Spratlin JL, Serkova NJ, Eckhardt SG. Clinical applications of metabolomics in oncology: a review. Clinical Cancer Research. 2009;15(2):431–440. [PMC free article] [PubMed]
152. Griffin JL, Kauppinen RA. Tumour metabolomics in animal models of human cancer. Journal of Proteome Research. 2007;6(2):498–505. [PubMed]
153. Heiden MGV, Cantley LC, Thompson CB. Understanding the warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029–1033. [PMC free article] [PubMed]
154. McFate T, Mohyeldin A, Lu H, et al. Pyruvate dehydrogenase complex activity controls metabolic and malignant phenotype in cancer cells. Journal of Biological Chemistry. 2008;283(33):22700–22708. [PubMed]
155. Sreekumar A, Poisson LM, Rajendiran TM, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009;457(7231):910–914. [PMC free article] [PubMed]

Articles from Journal of Skin Cancer are provided here courtesy of Hindawi Publishing Corporation